Vol. 4, Issue 1, 2016February 01, 2016 EDT
Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
1.
Rubio-Terrés C, Graefenhain de Codes R, Rubio-Rodríguez D, Evers T, Grau Cerrato S. Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain. JHEOR. 2016;4(1):19-34. doi:10.36469/9823